2023

• patent2023/06/05

  European Patent Office Grants Expansion of AskAt’s EP4 Receptor Antagonist Use Patent for the Treatment of Cancer

  AskAt received a communication under Rule 71(3) EPC dated May 19, 2023
  from the European Patent Office, with which the grant of the European patent is proposed. This grant of European Patent Application No. 18191714.7 is an EP4 receptor antagonist use patent for the treatment of cancer, particularly for the use of grapiprant in the treatment of epithelial cancer

• business2023/05/19

  Oxford Cannabinoid Technologies to Initiate First-In-Human Clinical Trial for Cannabinoid CB2 Receptor Agonist AAT-730 in the United Kingdom

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO：Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) and the Wales Research Ethics Committee 2 (REC 2) have approved the combined Phase I clinical trial application for AAT-730 (OCT461201).

• patent2023/05/15

  Korean Intellectual Property Office Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received a Notice of Allowance dated May 1, 2023 from the Korean
  Intellectual Property Office (KIPO) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Korean Patent Application No. 10-2021-7026299 (Filing Date: January 20, 2020).

• patent2023/04/17

  Mexican Patent and Trademark Office Grants AskAt an AAT-076 Production Process Patent

  AskAt received a Notice of Allowance for a Mexican patent dated April 11, 2023 from the National Institute of Indigenous Peoples (Instituto Nacional de los Pueblos Indígenas, INPI). The patent covers a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Application Number MX/a/2021/008612 (Filing Date: January 20, 2020).

• ir2023/03/31

  10th period financial statement release

  10th period financial statement release

• patent2023/02/10

  Rospatent Grants AskAt a Patent for the AAT-076 Production Process

  AskAt received an Official Decision of Grant dated February 1, 2023 from the Russian Federal Service for Intellectual Property, Patents and Trademarks (Rospatent) for a process for the differential solubility-driven asymmetric transformation of substituted 2H-chromene-3-carboxylic acids. The notice was issued in connection with Russian Patent Application No. 2021124682 (Filing Date: January 20, 2020).

• business2023/01/11

  Combined Clinical Trial Application of Cannabinoid CB2 Receptor Agonist AAT-730 for First-In-Human Clinical Trial has been submitted by Oxford Cannabinoid Technologies to UK Regulatory Agencies

  Oxford Cannabinoid Technologies Holdings plc, the pharmaceutical company developing prescription cannabinoid medicines in pain markets (headquarter: London, UK; CEO：Clarissa Sowemimo-Coker; OCT), which licensed AskAt’s cannabinoid CB2 receptor agonist AAT-730 for human use, announced that a combined clinical trial application for AAT-730 (OCT461201) has been successfully submitted to UK Medicines & Healthcare products Regulatory Agency (MHRA) and Research Ethics Committee (REC) on January 4th, 2023.

• science2023/01/11

  Ikena Oncology presented results of a clinical trial of grapiprant (AAT-007/IK-007) in patients with advanced microsatellite stable colorectal cancer

  Ikena Oncology presented results of a clinical trial of IK-007 in patients with advanced microsatellite stable colorectal cancer at ESMO Immuno-Oncology Annual Congress 2022. For details, please refer an abstract of the presentation at congress homepage.

• patent2023/01/06

  European Patent Office Grants AskAt EP4 Receptor Antagonist Use Patent for the Treatment of Cartilage Disease

  AskAt received a notice of the decision to grant a European patent pursuant to Article 97(1) EPC from the European Patent Office as of December 8, 2022. This grant of European Patent Application No. 14768803.0 (Filing Date: March 19, 2014), is an EP4 receptor antagonist use patent for the treatment of cartilage disease.